Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) received acclamation for its outstanding innovative achievements among the pharmaceutical field. Recently, Fosun Pharma ranked sixth in the China Food and Drug Administration Southern Medicine Economic Institute’s selection of “Top Ten Most Innovative Pharmaceutical Enterprises”.

With a candidate pool based on the “Top 100 Pharmaceutical Companies in China”, the selection analyzed candidates’ scale parameter, input parameter, output parameter and premium parameter through TOPSIS and calculated their respective comprehensive TOPSIS scores. The ten companies with the highest composite scores are selected as the “China’s Most Innovative Pharmaceutical Enterprises”.

In recent years, Fosun Pharma’s main business development strategy has been increasingly prominent, and it has focused more on pharmaceuticals core research and innovation capacity building. In 2012, Fosun Pharma’s medical products and R&D business achieved operating income of RMB4,678 million, reaching growth of 20.98% compared to year 2011. The overall R&D investment was RMB370 million in 2012, and the annual R&D investment accounted for 7% to 9% of pharmaceutical business operating income. The company owns 1,545 professionals in R&D and 766 of them are pharmaceutical research talents; of which 143 hold senior titles and 33 hold doctor degrees, forming a sound talent base. In 2012, there are 70 patents in pharmaceutical sector and 60 of them are invention patents; In addition, there are 33 patent authorizations and 28 of them are invention patents.

Fosun Pharma always takes independent innovation as the driving force of corporate development. In China, Fosun Pharma has achieved competitive advantage for the market segments of liver disease, diabetes, tuberculosis and clinical diagnostic products; while in the global market, Fosun Pharma has also become a market leader in antimalarial drug. As biopharmaceutical market has become main competition in the worldwide pharmaceutical field, Fosun Pharma is committed to building leading biomedical R&D regime in China and will focus on the R&D on macromolecular biological drugs, small molecule chemical medicine and other generic drugs with high technological barriers-to-entry.